# XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)

> **NCT03399110** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 1024 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03399110
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-11-17
- **Primary completion:** 2026-07-25
- **Final completion:** 2026-07-25
- **Target enrollment:** 1024 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03399110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03399110, "XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03399110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*